ClinicalTrials.gg
Not yet recruitingNCT07645833PRIMAUpdated Jun 12, 2026

Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension

A Phase 3 interventional study of Eptinezumab and Placebo in Idiopathic Intracranial Hypertension (IIH), sponsored by Rigmor Højland Jensen. Not yet recruiting. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Rigmor Højland Jensen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to learn if eptinezumab can reduce headache frequency and headache-related disability in adults with idiopathic intracranial hypertension (IIH) and chronic headache. It will also evaluate the safety and tolerability of eptinezumab in this patient population.

The main questions it aims to answer are:

  • Does eptinezumab reduce the number of monthly moderate-to-severe headache days compared with placebo?
  • Does eptinezumab improve headache-related disability and patient-reported outcomes?
  • What adverse events occur during treatment with eptinezumab?

Researchers will compare eptinezumab to placebo to determine whether eptinezumab is effective in the prevention of chronic headache in patients with IIH.

Participants will:

  • Receive eptinezumab or placebo according to random assignment.
  • Attend scheduled study visits and clinical assessments.
  • Complete headache diaries and questionnaires during the study period.
  • Undergo study-related examinations and collection of biological samples, including blood samples.
02

Conditions studied

  • Idiopathic Intracranial Hypertension (IIH)

Browse trials for

03

In context

Pseudotumor Cerebri

54 studies on the registry are indexed under Pseudotumor Cerebri; 23 are open to participants now.

This study's planned enrollment of 96 is above the median of 60 across 36 interventional studies indexed under Pseudotumor Cerebri.

Browse Pseudotumor Cerebri studies →

Lead sponsor

Rigmor Højland Jensen is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, aged 18 to 55 years
  • Diagnosis of idiopathic intracranial hypertension (IIH) or IIH without papilledema
  • Chronic headache associated with IIH
  • At least 15 headache days per monthduring the screening period
  • At least 8 migraine-like headache days per month during the screening period
  • Use of effective througout the trial period and for at least 5 months after last administration of study drug

Exclusion criteria

Exclusion Criteria:

  • Non-compliance with headache diary completion during screening, defined as less than 80% of the days reported
  • to receiving eptinezumab according to the Summary of Product Characteristics
  • Previous or current treatment with anti-CGRP monoclonal antibodies within 5 half-lives
  • Previous insufficient or non-effective treatment with eptinezumab
  • Pregnancy, breastfeeding, or planning pregnancy during the sudy period
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Eptinezumab

    Participants will receive eptinezumab 300 mg administered intravenously during the double-blind treatment period

    Drug: Eptinezumab

  • Placebo comparator
    Placebo

    Participants will receive matching placebo (0,9% saline) administered intravenously during the double-blind period

    Drug: Placebo

Interventions

  • Eptinezumab 300 mg. administered as an intravenous infusion in 100 ml. saline solution at baseline and at week 12 during the double-blind treatment period. participants may subsequently receive open-label eptinezumab according to the study protocol

  • DrugPlacebo

    Matching placebo (0.9% saline solution) administered intravenously

06

What researchers measure

Primary outcomes

  1. Mean monthly-to-severe headache days

    Mean monthly number of moderate-to-severe headache days, defined as any day with headache of moderate or severe intensity or requiring acute headache medication, assessed using daily diary recordings

    Time frame: Weeks 1 to 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — A decision regarding sharing of individual participant data has not yet been made. Any future sharing of de-identified data will be subject to applicable data protection regulations, ethical approvals, and institutional policies.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 12, 2026
StartEst.
Jun 22, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jan 2029
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07645833
Lead sponsor
Rigmor Højland Jensen
Responsible party
Rigmor Højland Jensen (Ass.Professor, Dr. Med., Principal Investigator and Sponsor, Danish Headache Center) — Sponsor-investigator
First posted
Jun 12, 2026
Start date
Jun 22, 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jun 12, 2026

Study contacts

Frederik P.T. Jantzen, Md.
Contact
frederik.peter.thal.jantzen@regionh.dk
+4538633555
Rigmor H Jensen, Ass.Professor, Dr.Med.
principal investigator · Danish Headache Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion